α-Galactosidase A Deficiency (Full Gene Sequencing)
Also known as: Anderson-Fabry Disease, Fabry Disease
Use
Indications for testing: Patients with clinical features of Fabry disease, both male and female; carrier testing for females with affected male relatives; patients with left ventricular hypertrophy or cardiomyopathy who otherwise do not have a classic Fabry disease phenotype; parents, siblings, and possibly children of a patient known to carry a mutation in GLA gene; prenatal testing when a parent is diagnosed with Fabry disease and has an identified GLA mutation.
Special Instructions
Testing schedules may vary, and additional time should be allowed for confirmatory or reflex tests. Turnaround time is defined from the date of specimen pickup to result release.
Limitations
This DNA sequencing method does not detect large deletions, large duplications, genomic rearrangements, or deep intronic variants. It may be affected by allele-dropout.
Methodology
NGS
Biomarkers
LOINC Codes
- 34515-7
- 34515-7
Result Turnaround Time
18-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL
Minimum Volume
Not provided
Container
Lavender-top (EDTA) tube or yellow-top (ACD) tube
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container
